Bavarian Nordic Initiates Phase I/II Clinical Trials With MVA-BN(R) Polytope Against HIV

Bavarian Nordic A/S announced today that the company has initiated a Phase I and a Phase I/II clinical study in Europe with MVA-BN® polytope vaccine against HIV. The vaccine was recently released from the company’s facility in Berlin for use in clinical trials. The purpose of these studies is to evaluate the safety and immunogenicity of the vaccine in healthy and HIV-infected subjects. Results from both studies are expected in the second half of 2007.